Verona Pharma plc (NASDAQ:VRNA - Get Free Report) CFO Mark W. Hahn sold 183,728 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $5.01, for a total transaction of $920,477.28. Following the completion of the transaction, the chief financial officer now owns 13,293,736 shares in the company, valued at $66,601,617.36. This represents a 1.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Verona Pharma Stock Performance
NASDAQ VRNA traded up $0.48 during trading on Friday, reaching $40.50. The company's stock had a trading volume of 626,985 shares, compared to its average volume of 939,445. Verona Pharma plc has a twelve month low of $11.39 and a twelve month high of $40.76. The firm has a market cap of $3.31 billion, a price-to-earnings ratio of -21.09 and a beta of 0.46. The business's fifty day moving average price is $35.74 and its 200-day moving average price is $26.18. The company has a debt-to-equity ratio of 0.93, a quick ratio of 12.88 and a current ratio of 13.03.
Verona Pharma (NASDAQ:VRNA - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The company had revenue of $5.62 million during the quarter, compared to analysts' expectations of $2.31 million. During the same quarter in the previous year, the business earned ($0.18) EPS. As a group, analysts anticipate that Verona Pharma plc will post -2.11 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts recently commented on VRNA shares. HC Wainwright increased their target price on shares of Verona Pharma from $36.00 to $42.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. Canaccord Genuity Group raised their price objective on Verona Pharma from $37.00 to $44.00 and gave the stock a "buy" rating in a report on Tuesday, November 5th. Truist Financial boosted their target price on Verona Pharma from $38.00 to $44.00 and gave the company a "buy" rating in a report on Wednesday, October 9th. Finally, Wells Fargo & Company upped their target price on Verona Pharma from $50.00 to $64.00 and gave the company an "overweight" rating in a research report on Tuesday, November 5th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Verona Pharma presently has an average rating of "Buy" and an average price target of $43.83.
Get Our Latest Stock Report on Verona Pharma
Institutional Investors Weigh In On Verona Pharma
Several large investors have recently modified their holdings of VRNA. Mirae Asset Global Investments Co. Ltd. grew its position in Verona Pharma by 25.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company's stock valued at $75,000 after buying an additional 529 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Verona Pharma by 70.6% in the 3rd quarter. GAMMA Investing LLC now owns 1,336 shares of the company's stock worth $38,000 after acquiring an additional 553 shares during the period. CWM LLC purchased a new stake in shares of Verona Pharma in the second quarter valued at about $29,000. EMC Capital Management acquired a new position in shares of Verona Pharma during the second quarter worth about $38,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Verona Pharma by 37.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,041 shares of the company's stock worth $605,000 after purchasing an additional 5,691 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.
About Verona Pharma
(
Get Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Verona Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma wasn't on the list.
While Verona Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
